IPA Provides Update on Growth Strategy and Recent Share Price Movement
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments.
- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments.
- IPA remains committed to expanding its contract research organization (CRO) capabilities and leveraging technology to drive innovation and efficiency.
- The IPA strategy of providing highly specialized full-service antibody discovery and development, while gaining a competitive edge for profitable growth through technology and scale, continues to pay off.
- IPA does not believe the recent drop in stock price matches the value creation it is building with its growth strategy.